Validation of the Bleeding Risk and Mortality in the Use of Warfarin and Antiplatelet Agents in Hemodialysis Patients

Validation of the Bleeding Risk and Mortality in the Use of Warfarin and Antiplatelet Agents in Hemodialysis Patients - Validation of the bleeding risk and mortality in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023916

Enrollment

300

Registered

2016-09-10

Start date

2016-02-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal failure on hemodialysis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with end stage renal failure who underwent hemodialysis at baseline.

Exclusion criteria

Exclusion criteria: Patients who did not give informed consent, and who were lost to follow up due to a transfer to other institutions.

Design outcomes

Primary

Measure	Time frame
Bleeding events during the follow-up period	—

Secondary

Measure	Time frame
All-cause death	—

Countries

Japan

Contacts

Public ContactYoriko Horiguchi

Sagami Junkanki Clinic Department of Internal Medicine

dzq04361@nifty.com0427462211

Outcome results